TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06887192: A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

Sponsor: MapLight Therapeutics · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,987,600

Rescue Site Savings

+$1,978,800

Unlock Full NCT06887192 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06887192 Rescue Dossier →